Efficiency of anti-VEGF therapy in central nervous system AML relapse: A case report and literature review

Han-Yu Cao; Tao Tao; Xiang-Dong Shen; Lian Bai; Chao-Ling Wan; De-Pei Wu; Jin-Li Li; Sheng-Li Xue

doi:10.1002/ccr3.5367

Efficiency of anti-VEGF therapy in central nervous system AML relapse: A case report and literature review

Clin Case Rep. 2022 Feb 3;10(2):e05367. doi: 10.1002/ccr3.5367. eCollection 2022 Feb.

Authors

Han-Yu Cao^{1

2}, Tao Tao³, Xiang-Dong Shen^{1

2}, Lian Bai⁴, Chao-Ling Wan^{1

2}, De-Pei Wu^{1

2}, Jin-Li Li⁵, Sheng-Li Xue^{1

2}

Affiliations

¹ National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.
² Institute of Blood and Marrow Transplantation Collaborative Innovation Center of Hematology Soochow University Suzhou China.
³ Department of Respiratory Medicine The Fifth People's Hospital of Suzhou Suzhou China.
⁴ Department of Hematology Canglang Hospital of Suzhou Suzhou China.
⁵ Department of Radiation Oncology The First Affiliated Hospital of Soochow University Suzhou China.

Abstract

There have been few reports on the treatment of central nervous system (CNS) acute myeloid leukemia (AML) relapse. This case study demonstrates that bevacizumab may be a viable treatment option when combined with IT chemotherapy as maintenance therapy for those with CNS leukemia.

Keywords: AML; anti‐VEGF therapy; bevacizumab; central nervous system (CNS).

Publication types

Case Reports